en
E-mail us
cn

Impact of Solid-state in Early Development

API phase and formulation should be able to reach desired exposures and have adequate chemical and physical stability for GLP toxicology and first in human (FIH) studies. Any changes to form or formulation will incur significant time and resource penalties.

Access the Full Content
* Required
By submitting this form, you acknowledge that your information will be used to provide the requested content and may be processed as described in our Privacy Policy.
Contact Us
bd_global@crystalpharmatech.com +1-609-604-8303
U.S
NJ Sites: Suite 500-B, 3000 Eastpark Blvd, Cranbury, New Jersey, USA 08512
2005 Eastpark Blvd, Cranbury, New Jersey, USA 08512
CA Site: 7133 Koll Center Parkway, Suite 200, Pleasanton, California, USA 94566
Canada
6800 Kitimat Rd, Unit 1, Mississauga, Ontario, Canada L5N 5M1
China
No. 288, Jiangyun Road, Suzhou Industrial Park, Suzhou, China 215123
NJ Sites: Suite 500-B, 3000 Eastpark Blvd, Cranbury, New Jersey, USA 08512
2005 Eastpark Blvd, Cranbury, New Jersey, USA 08512
CA Site: 7133 Koll Center Parkway, Suite 200, Pleasanton, California, USA 94566
bd_global@crystalpharmatech.com +1-609-604-8303
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. Part of the tracking is necessary to ensure SEO effectiveness,
By using this site, you agree to our use of cookies. Visit our cookie policy to learn more.
Reject Accept